Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07059494 · ClinicalTrials.gov registry record · Phase 4
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
A Phase 4 study of Hepatocellular Carcinoma, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT07059494: Recruiting Phase 4 study of Hepatocellular Carcinoma, sponsored by Icahn School of Medicine at Mount Sinai.
NCT07059494 is a Phase 4 study of Hepatocellular Carcinoma that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 40 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07059494, a Phase 4 study of Hepatocellular Carcinoma, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
A single institution, single arm, two-cohort feasibility trial to evaluate the combination of locoregional Y\^90 therapy with systemic atezolizumab and bevacizumab, in participants presenting with hepatocellular carcinoma (HCC) 1) within Milan Criteria (MC) with AFP ≥ 400 ng/ml as a means of bridge therapy prior to transplant, 2) beyond the Milan Criteria (MC) (within USCF DS criteria and all comers), as a means of downstaging prior to liver transplantation.
Primary Outcome
Cohort A Proportion of participants downstaging to within Milan Criteria as assessed by the rate of radiographic response via CT/MRI pre transplantation (efficacy window of assessment = 9 months from first cycle of Y\^90) Cohort B Response rate to treatment in participants within MC with AFP ≥ 400 ng/ml defined by CT/MRI and a decrease in AFP ≥ 50 percent (efficacy window of assessment = 9 months from first cycle of Y\^90)
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- RADIATION Y^90 Radioembolization
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-06 |
| Est. Completion | 2028-08-01 |
| Phase | Phase 4 |
What NCT07059494 shows while recruiting
NCT07059494 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT07059494 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07059494 about?
NCT07059494 is a clinical study titled "Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant". A single institution, single arm, two-cohort feasibility trial to evaluate the combination of locoregional Y\^90 therapy with systemic atezolizumab and bevacizumab, in participants presenting with hepatocellular carcinoma (HCC) 1) within Milan Criteria (MC) with AFP ≥ 400 ng/ml as a means of bridge ...
What is the current status of trial NCT07059494?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2026-06. Estimated completion is 2028-08-01.
What conditions does trial NCT07059494 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT07059494?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Y^90 Radioembolization (RADIATION).
Who is sponsoring clinical trial NCT07059494?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07059494 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07059494's enrollment target sits among peer trials
40 91st of 145 higher than 48 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
RECRUITING · Phase 4
-
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
COMPLETED · Phase 4
-
Molecular Basis of Pediatric Liver Cancer
RECRUITING
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia